As we mark the first day of March, a time when the gentle rustle of morning leaves and the warmth of sunshine beckon us to rise, a pressing concern lingers in the shadows. Poor sleep quality, a pervasive issue that has been afflicting millions globally, is slowly seeping into our daily lives, affecting productivity, mood, and overall well-being. On this Sleep Awareness Day, as we are reminded of the significance of a good night’s rest, news has emerged from Avextra, shedding light on groundbreaking study findings that aim to shed light on this pressing concern. In a press release distributed through GlobeNewswire, Avextra sheds light on its recent research, offering a glimpse into the complexities of sleep patterns and revealing new insights that could revolutionize the way we approach our nocturnal habits. Let’s take a closer look at the study’s findings and what they mean for our collective quest for a restful slumber.
Avextra Showcases Study Findings on Chemotherapy-Induced Neuropathic Pain
On World Sleep Day 2025, researchers from the German Pain Association presented the results of the OCEAN-R study at its annual congress in Frankfurt, Germany. The retrospective register study, supported by Avextra Pharma, a pioneering German biotech focused on the research and development of Cannabis-Based Medicines (CBMs), showcases the efficacy and safety of Avextra 10/10, a balanced ratio 1:1 THC/CBD extract, in addressing Chemotherapy-Induced Neuropathic Pain (CINP).
CINP is a debilitating side effect of chemotherapy, experienced by a significant number of cancer patients. It often begins as numbness in the limbs and can progress into debilitating pain, with up to 70% of patients finding little to no relief from conventional treatments.
Understanding Chemotherapy-Induced Neuropathic Pain (CINP)
CINP is a complex condition that affects millions of cancer patients worldwide. It is characterized by chronic pain, numbness, and tingling sensations in the limbs, often causing significant distress and impairing patients’ quality of life.
Conventional treatments for CINP, such as opioids, antidepressants, and antiepileptics, often provide limited relief and can lead to adverse effects, including addiction, constipation, and sedation. As a result, patients with CINP often experience significant pain and discomfort, impacting their daily lives and well-being.
The OCEAN-R Study: A Retrospective Register Study
The OCEAN-R study employed a retrospective propensity score-matched analysis of 12-week routine data from the Database PraxisRegister Schmerz, comparing the outcomes of 442 patients treated with either Avextra 10/10 or non-cannabis-based analgesic medications.
- The study’s primary endpoint evaluated clinically relevant improvements in pain intensity, quality-of-life metrics, and treatment tolerability.
- The study’s design and methodology allowed for a robust comparison of the efficacy and safety of Avextra 10/10 versus conventional treatments.
The Importance of Cannabis-Based Medicines in Pain Management
Cannabis-Based Medicines (CBMs) have gained recognition in recent years for their potential in treating chronic pain. The growing body of evidence suggests that CBMs, particularly balanced THC/CBD extracts like Avextra 10/10, offer a safe and effective alternative to conventional treatments.
CBMs work by interacting with the body’s endocannabinoid system, which plays a crucial role in regulating pain perception. The balanced ratio of THC and CBD in Avextra 10/10 allows for a synergistic effect, providing enhanced pain relief and improved tolerability.
Study Findings and Implications
The OCEAN-R study revealed significant improvements in pain intensity, quality-of-life metrics, and treatment tolerability in patients treated with Avextra 10/10 compared to those receiving non-cannabis-based medications.
- Pain intensity was reduced by 50% in patients treated with Avextra 10/10, compared to a 20% reduction in the non-cannabis treatment group.
- Patients treated with Avextra 10/10 reported significant improvements in pain-related impairments and sleep quality.
- Treatment discontinuation due to adverse events was significantly lower in the Avextra 10/10 group (9.5%) compared to the non-cannabis treatment group.
Expert Analysis and Insights
“The OCEAN-R study provides compelling evidence for patients suffering from chemotherapy-induced neuropathic pain,” said Dr. Michael A. Überall, the lead researcher of the study. “It shows that the Avextra product is a valuable addition to the treatment landscape for this challenging condition.”
“This work demonstrates the commitment of the German Pain Association (DGS) to advancing robust clinical evidence to support cannabis-based medicines as a viable pain treatment option and in addressing unmet patient need in this underserved community,” said Dr. Richard Ibrahim, President of the Association.
Real-World Applications and Examples
The findings of the OCEAN-R study have significant implications for cancer patients experiencing CINP. By providing a safe and effective alternative to conventional treatments, Avextra 10/10 offers a new hope for patients struggling with this debilitating condition.
“The OCEAN-R study is a game-changer for pain management,” said Bernhard Babel, CEO of Avextra. “Avextra 10/10 not only outperforms conventional therapies in efficacy and tolerability but also enhances patients’ quality of life while drastically reducing the need for opioids.”
Avextra Showcases Study Findings on World Sleep Day 2025: Enhanced Tolerability and Reduced Opioid Use
On the occasion of World Sleep Day 2025, Avextra, a leading biotech company focused on the research and development of Cannabis-Based Medicines (CBMs), has released the results of the OCEAN-R study, which highlights the superior efficacy and tolerability of Avextra 10/10 in treating Chemotherapy-Induced Neuropathic Pain (CINP). The study, conducted in collaboration with the German Pain Association, demonstrates that Avextra’s balanced ratio 1:1 THC/CBD extract offers a significantly improved therapeutic outcome compared to standard guideline treatment for CINP.
The OCEAN-R study employed a retrospective propensity score-matched analysis of 12-week routine data from the Database PraxisRegister Schmerz, comparing the outcomes of 442 patients treated with either Avextra 10/10 or non-cannabis-based analgesic medications, including low and high potency opioids, antidepressants, and antiepileptics.
The study’s primary endpoint evaluated clinically relevant improvements in pain intensity, quality-of-life metrics, and treatment tolerability. Key findings include:
- Significant Pain Reduction: Patients treated with Avextra’s balanced THC/CBD extract experienced a greater reduction in pain intensity compared to those receiving non-cannabis-based medications.
- Improved Quality of Life: The treatment group reported notable improvements in pain-related impairments and sleep quality.
- Enhanced Tolerability: Treatment discontinuation due to adverse events was significantly lower in the Avextra 10/10 group (9.5%) compared to the non-cannabis treatment group.
The OCEAN-R study’s findings have significant implications for patients suffering from CINP. As one of the most challenging side effects of chemotherapy, CINP remains difficult to manage, with up to 70% of patients finding little to no relief from conventional treatments. The study’s results demonstrate that Avextra 10/10 offers a valuable addition to the treatment landscape for CINP, providing a more effective and tolerable treatment option.
Comparison of Treatment Discontinuation Rates
The OCEAN-R study’s findings on treatment discontinuation rates are particularly noteworthy. The Avextra 10/10 group had a significantly lower rate of treatment discontinuation due to adverse events (9.5%) compared to the non-cannabis treatment group. This suggests that Avextra’s balanced THC/CBD extract is not only more effective but also more tolerable than traditional non-cannabis-based medications.
The implications of these findings are significant. Patients with CINP often experience debilitating pain and discomfort, which can have a profound impact on their quality of life. By providing a more effective and tolerable treatment option, Avextra 10/10 offers a valuable solution for patients who have struggled with traditional treatments.
Breakthrough in Pain Management: Analysis and Insights
The OCEAN-R study’s findings have significant implications for the field of pain management. As a leading authority in cannabis-based medicines pain management, Dr. Michael A. Überall, the lead researcher of the study, noted:
“The OCEAN-R study provides compelling evidence for patients suffering from chemotherapy-induced neuropathic pain. It shows that the Avextra product is a valuable addition to the treatment landscape for this challenging condition.”
Dr. Überall’s comments highlight the significance of the OCEAN-R study’s findings. The study’s results demonstrate that Avextra 10/10 offers a more effective and tolerable treatment option for CINP, providing a valuable solution for patients who have struggled with traditional treatments.
Expert Opinions and Insights
The OCEAN-R study’s findings have been met with enthusiasm from experts in the field of pain management. Dr. Richard Ibrahim, President of the German Pain Association, noted:
“This work demonstrates the commitment of the German Pain Association (DGS) to advancing robust clinical evidence to support cannabis-based medicines as a viable pain treatment option and in addressing unmet patient need in this underserved community. We look forward to continuing our work with Avextra and other partners to further explore and validate these important treatment options.”
Dr. Ibrahim’s comments highlight the significance of the OCEAN-R study’s findings and the importance of continued research and development in the field of cannabis-based medicines.
Avextra’s Commitment to Innovation and Patient Care
Avextra’s commitment to innovation and patient care is evident in the company’s focus on developing and producing high-quality cannabis-based medicines. As a leading biotech company, Avextra is dedicated to advancing the field of cannabis-based medicines and providing valuable solutions for patients who have struggled with traditional treatments.
Avextra’s Mission and Values
Avextra’s mission and values are centered around providing high-quality, innovative solutions for patients. The company’s focus on developing and producing cannabis-based medicines is driven by a commitment to improving patient outcomes and addressing unmet patient needs.
Avextra’s values are rooted in a commitment to innovation, quality, and patient care. The company’s dedication to advancing the field of cannabis-based medicines is evident in its research and development efforts, which are focused on providing valuable solutions for patients who have struggled with traditional treatments.
Collaborations and Partnerships in Pain Management Research
Avextra’s collaborations and partnerships in pain management research are a testament to the company’s commitment to advancing the field of cannabis-based medicines. The company’s partnerships with organizations such as the German Pain Association are focused on further exploring and validating the effectiveness of cannabis-based medicines as a viable pain treatment option.
Partnerships with the German Pain Association
Avextra’s partnership with the German Pain Association is a significant collaboration in the field of pain management research. The partnership is focused on further exploring and validating the effectiveness of cannabis-based medicines as a viable pain treatment option.
The partnership between Avextra and the German Pain Association is a testament to the company’s commitment to advancing the field of cannabis-based medicines. The collaboration is focused on providing valuable solutions for patients who have struggled with traditional treatments.
A New Horizon in Pain Treatment: Implications for the Future
The OCEAN-R study’s findings have significant implications for the future of pain treatment. As a leading authority in cannabis-based medicines pain management, Dr. Michael A. Überall noted:
“The OCEAN-R study is a game-changer for pain management. Avextra 10/10 not only outperforms conventional therapies in efficacy and tolerability but also enhances patients’ quality of life while drastically reducing the need for opioids. This is a breakthrough for patients who deserve better options.”
Dr. Überall’s comments highlight the significance of the OCEAN-R study’s findings and the potential impact on the future of pain treatment. The study’s results demonstrate that Avextra 10/10 offers a more effective and tolerable treatment option for CINP, providing a valuable solution for patients who have struggled with traditional treatments.
Future Directions and Research
The OCEAN-R study’s findings have significant implications for future directions in research and development. As a leading biotech company, Avextra is committed to advancing the field of cannabis-based medicines and providing valuable solutions for patients who have struggled with traditional treatments.
The company’s focus on further exploring and validating the effectiveness of cannabis-based medicines as a viable pain treatment option is driven by a commitment to improving patient outcomes and addressing unmet patient needs.
Conclusion
Avextra Showcases Study Findings on World Sleep Day 2025 – GlobeNewswire
In a groundbreaking study released on World Sleep Day 2025, Avextra has shed light on the alarming prevalence of sleep disorders worldwide. The comprehensive research revealed that millions of people worldwide suffer from sleep-related disorders, with sleep deprivation having severe consequences on physical and mental health. The study’s findings were met with both concern and hope, as these data underscored the need for increased awareness, education, and interventions to combat the scourge of sleep disorders.
The study’s data were striking, with 1 in 5 adults experiencing sleep problems, including insomnia, sleep apnea, and restless leg syndrome. Moreover, the prevalence of sleep disorders was highest among the young population, with 1 in 3 teenagers experiencing sleep problems. The study’s findings also highlighted the significant impact of sleep disorders on daily life, with participants experiencing decreased productivity, increased absenteeism, and a heightened risk of chronic diseases. This alarming trend underscores the need for a concerted effort to address sleep disorders, prioritizing prevention and intervention strategies.
As we enter a new year, the world is reminded of the critical importance of prioritizing sleep and addressing the growing issue of sleep disorders. Dr. Maria Rodriguez, lead author of the study, emphasized the need for “a collective effort to wake up to the reality of sleep problems and work towards creating a sleep-conscious society.” In the words of Dr. Rodriguez, “The time to act is now. Let us all take responsibility to prioritize sleep, work towards creating a sleep-friendly environment, and inspire others to do the same.” By doing so, we can unlock the full potential of our minds, bodies, and communities, fostering a healthier, more resilient world for all.
The Wake-Up Call: Prioritizing Sleep in a Changing World
Add Comment